Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Axsome Therapeutics (AXSM) EBIAT (2022 - 2025)

Axsome Therapeutics' EBIAT history spans 4 years, with the latest figure at -$28.6 million for Q4 2025.

  • For Q4 2025, EBIAT rose 61.88% year-over-year to -$28.6 million; the TTM value through Dec 2025 reached -$183.2 million, up 36.22%, while the annual FY2025 figure was -$183.2 million, 36.22% up from the prior year.
  • EBIAT for Q4 2025 was -$28.6 million at Axsome Therapeutics, up from -$47.2 million in the prior quarter.
  • Across five years, EBIAT topped out at -$11.2 million in Q1 2023 and bottomed at -$98.7 million in Q4 2023.
  • The 4-year median for EBIAT is -$60.3 million (2022), against an average of -$56.0 million.
  • The largest annual shift saw EBIAT surged 71.69% in 2023 before it crashed 509.35% in 2024.
  • A 4-year view of EBIAT shows it stood at -$61.2 million in 2022, then tumbled by 61.09% to -$98.7 million in 2023, then grew by 24.06% to -$74.9 million in 2024, then soared by 61.88% to -$28.6 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's EBIAT are -$28.6 million (Q4 2025), -$47.2 million (Q3 2025), and -$48.0 million (Q2 2025).